Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 0.54 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | CLK3 | P49761 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.54 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NAT1 | P18440 | 4/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101026 | 1.00 | PIM1 (0.54) | PIM1HASPINPIK3CDCSNK2A2PIK3CA | |
| SCHEMBL23582995 | 1.00 | PIM1 (0.54) | PIM1HASPINPIK3CDCSNK2A2PIK3CA | |
| SCHEMBL4959430 | 1.00 | PIM1 (0.54) | PIM1HASPINPIK3CDCSNK2A2PIK3CA | |
| SCHEMBL23582994 | 1.00 | PIM1 (0.54) | PIM1HASPINPIK3CDCSNK2A2PIK3CA | |
| SCHEMBL23578825 | 0.87 | CHEK1 (0.56) | PIM1HASPINPIK3CDCSNK2A2PIK3CA | |
| SCHEMBL23578828 | 0.87 | CHEK1 (0.56) | PIM1HASPINPIK3CDCSNK2A2PIK3CA | |
| SCHEMBL12506274 | 0.85 | CHEK1 (0.54) | HASPINCSNK2A2CSNK2BCSNK2A1CHEK1 | |
| SCHEMBL23582947 | 0.81 | PIM1 (0.55) | PIM1HASPINPIK3CDCSNK2A2PIK3CA | |
| SCHEMBL23579145 | 0.81 | PIM1 (0.55) | PIM1HASPINPIK3CDCSNK2A2PIK3CA | |
| SCHEMBL23582949 | 0.81 | PIM1 (0.55) | PIM1HASPINPIK3CDCSNK2A2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | claimed |
| EP-4083037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | Yonsei University, University-Industry Foundation(UIF). (KR) | 2022-11-02 | — | — | EP | claimed |
| CN-114945569-A | Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or Tau-protein related diseases comprising same | 延世大学校产学协力团 | 2022-08-26 | — | — | CN | claimed |
| WO-2021133037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | 연세대학교 산학협력단 | 2021-07-01 | — | — | WO | claimed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| EP-4083037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | Yonsei University, University-Industry Foundation(UIF). (KR) | 2022-11-02 | — | — | EP | disclosed |
| EP-4083037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | Yonsei University, University-Industry Foundation(UIF). (KR) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021133037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | 연세대학교 산학협력단 | 2021-07-01 | — | — | WO | disclosed |
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | disclosed |
| EP-1805175-B1 | NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | disclosed |
| EP-1805175-B1 | NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | disclosed |
| US-7247727-B2 | Azaindole thiazolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247727-B2 | Azaindole thiazolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247727-B2 | Azaindole thiazolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | disclosed |
| US-20060084674-A1 | Azaindole thiazolinones | CHEN SHAOQING | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | MAPT, APP, PRNP | PIM1 3071/4885HASPIN 1208/4885PIK3CD 2247/4885 |
| US-20060084674-A1 | Azaindole thiazolinones | CDK1, CDK2, CDK12 | PIM1 695/4885HASPIN 505/4885PIK3CD 692/4885 |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K6, MAP3K1 | PIM1 709/4885HASPIN 1268/4885PIK3CD 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.